Bolt Biotherapeutics (BOLT) Current Assets (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Current Assets of $25.8 million for Q1 2026, down 14.9% sequentially from $30.3 million in Q4 2025, and down 39.42% YoY from $42.5 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Current Assets (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Current Assets for 7 years, with the latest figure at $25.8 million in Q1 2026.
- Quarterly Current Assets fell 39.42% year-over-year to $25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (down 39.42% YoY) and the FY2025 annual result came in at $30.3 million, down 40.45% from the prior year.
- Current Assets fell to $25.8 million in Q1 2026 per BOLT's latest filing, from $30.3 million in the prior quarter.
- Over five years, Current Assets peaked at $196.1 million in Q1 2022 and troughed at $25.8 million in Q1 2026.
- A 5-year average of $98.3 million and a median of $95.1 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets slipped 8.68% in 2022, then plunged 55.28% in 2025.
- Over 5 years, Current Assets stood at $172.7 million in 2022, then tumbled by 38.81% to $105.7 million in 2023, then sank by 51.93% to $50.8 million in 2024, then slumped by 40.45% to $30.3 million in 2025, then retreated by 14.9% to $25.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $25.8 million, $30.3 million, and $35.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | 20.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.56 Mn |
| Mar 31, 2026 | 25.75 Mn |
| Dec 31, 2025 | 30.26 Mn |
| Sep 30, 2025 | 35.61 Mn |
| Jun 30, 2025 | 38.34 Mn |
| Mar 31, 2025 | 42.51 Mn |
| Dec 31, 2024 | 50.81 Mn |
| Sep 30, 2024 | 57.15 Mn |
| Jun 30, 2024 | 76.63 Mn |
| Mar 31, 2024 | 95.06 Mn |
| Dec 31, 2023 | 105.71 Mn |
| Sep 30, 2023 | 125.47 Mn |
| Jun 30, 2023 | 130.67 Mn |
| Mar 31, 2023 | 131.61 Mn |
| Dec 31, 2022 | 172.75 Mn |
| Sep 30, 2022 | 174.83 Mn |
| Jun 30, 2022 | 181.26 Mn |
| Mar 31, 2022 | 196.09 Mn |
| Dec 31, 2021 | 189.16 Mn |
| Sep 30, 2021 | 222.49 Mn |